Insider Selling: OmniAb, Inc. (NASDAQ:OABI) CEO Sells 41,811 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now owns 3,749,639 shares in the company, valued at $12,148,830.36. This trade represents a 1.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OmniAb Stock Down 0.6 %

Shares of NASDAQ:OABI traded down $0.02 during trading on Wednesday, hitting $3.20. 576,116 shares of the company traded hands, compared to its average volume of 413,324. OmniAb, Inc. has a one year low of $3.16 and a one year high of $6.55. The stock has a market capitalization of $451.90 million, a price-to-earnings ratio of -5.16 and a beta of -0.10. The business’s fifty day moving average is $3.69 and its 200-day moving average is $4.07.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th. Benchmark reissued a “buy” rating and set a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

Large investors have recently made changes to their positions in the company. CWC Advisors LLC. bought a new stake in OmniAb during the 3rd quarter valued at $54,000. Walleye Capital LLC acquired a new stake in OmniAb in the third quarter worth approximately $61,000. Intech Investment Management LLC bought a new stake in shares of OmniAb in the 3rd quarter worth $70,000. China Universal Asset Management Co. Ltd. boosted its position in shares of OmniAb by 64.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its position in OmniAb by 12.5% in the third quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock worth $104,000 after buying an additional 2,744 shares during the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.